HALO - Halozyme: The Upside Is Still There
Today, we will see why Halozyme Therapeutics (HALO) is an attractive pick in March 2020.
Company overview
Halozyme Therapeutics is a biopharmaceutical company that is leveraging its Enhanze drug delivery technology in collaboration with other pharmaceutical companies to develop and commercialize novel oncology therapies. The company has partnered with leading players such as Roche (RHHBY), Pfizer (PFE), Janssen, Baxalta, AbbVie (ABBV), Eli Lilly (LLY), Bristol-Myers Squibb (BMY), Alexion (ALXN) and argenx (ARGX) for its Enhanze drug delivery technology. The company's business model is based on recurring royalty revenues and milestone payments from partners